Phosphorylated Smad2 in Advanced Stage Gastric Carcinoma
Open Access
- 26 November 2010
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 10 (1), 652
- https://doi.org/10.1186/1471-2407-10-652
Abstract
Background Transforming growth factor β (TGFβ) receptor signaling is closely associated with the invasion ability of gastric cancer cells. Although Smad signal is a critical integrator of TGFβ receptor signaling transduction systems, not much is known about the role of Smad2 expression in gastric carcinoma. The aim of the current study is to clarify the role of phosphorylated Smad2 (p-Smad2) in gastric adenocarcinomas at advanced stages. Methods Immunohistochemical staining with anti-p-Smad2 was performed on paraffin-embedded specimens from 135 patients with advanced gastric adenocarcinomas. We also evaluated the relationship between the expression levels of p-Smad2 and clinicopathologic characteristics of patients with gastric adenocarcinomas. Results The p-Smad2 expression level was high in 63 (47%) of 135 gastric carcinomas. The p-Smad2 expression level was significantly higher in diffuse type carcinoma (p = 0.007), tumours with peritoneal metastasis (p = 0.017), and tumours with lymph node metastasis (p = 0.047). The prognosis for p-Smad2-high patients was significantly (p = 0.035, log-rank) poorer than that of p-Smad2-low patients, while a multivariate analysis revealed that p-Smad2 expression was not an independence prognostic factor. Conclusion The expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients with advanced gastric carcinoma.Keywords
This publication has 30 references indexed in Scilit:
- Inhibitory effect of a TGFβ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cellsBritish Journal of Cancer, 2010
- Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?Cancer Research, 2008
- TGFβ in CancerCell, 2008
- Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signalingProceedings of the National Academy of Sciences of the United States of America, 2007
- High TGFβ-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B GeneCancer Cell, 2007
- Lack of activated Smad2 in transforming growth factor-β signaling is an unfavorable prognostic factor in patients with esophageal squamous cell carcinomaJournal of Surgical Oncology, 2006
- Non-Smad TGF-β signalsJournal of Cell Science, 2005
- Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion‐stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cellsCancer Science, 2005
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Overexpression of Transforming Growth Factor-β1 in Scirrhous Carcinoma of the Stomach Correlates with Decreased SurvivalOncology, 1998